Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Bian, David J.H.; Lazaratos, Anna-Maria; Maritan, Sarah M.; Quaiattini, Andrea; Zeng, Zhimin; Zhu, Zhengfei; Sener, Ugur; Malani, Rachna; Kim, Yu Jung; Ichihara, Eiki; Cohen, Victor; Rose, April A.N.; Bouganim, Nathaniel; Dankner, Matthew

doi:10.1016/j.heliyon.2024.e29668

Heliyon

2024

DOI: 10.1016/j.heliyon.2024.e29668

|View full text |Cite

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

David J.H. Bian,

Anna-Maria Lazaratos,

Sarah M. Maritan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 184 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Leptomeningeal metastatic disease: new frontiers and future directions

Ozair,

Wilding,

Bhanja

et al. 2024

Nat Rev Clin Oncol

View full text Add to dashboard Cite

Leptomeningeal metastatic disease: new frontiers and future directions

Ozair,

Wilding,

Bhanja

et al. 2024

Nat Rev Clin Oncol

View full text Add to dashboard Cite

Radiotherapy and Systemic Treatment for Leptomeningeal Disease

Frechette,

Breen,

Brown

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Leptomeningeal disease (LMD) is a devastating sequelae of metastatic spread that affects approximately 5% of cancer patients. The incidence of LMD is increasing due to advancements in systemic therapy and enhanced detection methods. The purpose of this review is to provide a detailed overview of the evidence in the detection, prognostication, and treatment of LMD. A comprehensive literature search of PUBMED was conducted to identify articles reporting on LMD including existing data and ongoing clinical trials. We found a wide array of treatment options available for LMD including chemotherapy, targeted agents, and immunotherapy as well as several choices for radiotherapy including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and craniospinal irradiation (CSI). Despite treatment, the prognosis for patients with LMD is dismal, typically 2–4 months on average. Novel therapies and combination approaches are actively under investigation with the aim of improving outcomes and quality of life for patients with LMD. Recent prospective data on the use of proton CSI for patients with LMD have demonstrated its potential survival benefit with follow-up investigations underway. There is a need for validated metrics to predict prognosis and improve patient selection for patients with LMD in order to optimize treatment approaches.

show abstract

Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases

Bian,

Cohen,

Lazaratos

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a component of the treatment armamentarium for a subset of patients with metastatic disease. Emerging data suggest that some ADCs exhibit impressive activity even in central nervous system (CNS) metastases, a disease site that is difficult to treat and associated with poor prognosis. Herein, we describe and summarize the existing evidence surrounding ADCs in NSCLC with a focus on CNS activity.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Cited by 3 publications

References 184 publications

Leptomeningeal metastatic disease: new frontiers and future directions

Leptomeningeal metastatic disease: new frontiers and future directions

Radiotherapy and Systemic Treatment for Leptomeningeal Disease

Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases

Contact Info

Product

Resources

About